• Featured Product
  • KD/KO Validated

SLC22A18 Polyclonal antibody

SLC22A18 Polyclonal Antibody for WB, IP, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IP, IHC, ELISA

Conjugate

Unconjugated

Cat no : 11646-2-AP

Synonyms

BWR1A, BWSCR1A, HET, IMPT1, ITM, ORCTL 2, ORCTL2, p45 BWR1A, SLC22A18, SLC22A1L, TSSC5



Tested Applications

Positive WB detected inmouse brain tissue, COLO 320 cells
Positive IP detected inmouse brain tissue

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:1000-1:4000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

11646-2-AP targets SLC22A18 in WB, IP, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen SLC22A18 fusion protein Ag2245
Full Name solute carrier family 22, member 18
Calculated Molecular Weight 408 aa, 43 kDa
Observed Molecular Weight 40-50 kDa
GenBank Accession NumberBC015571
Gene Symbol SLC22A18
Gene ID (NCBI) 5002
RRIDAB_2191146
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

SLC22A18 is a member of the family of polyspecific organic-cation transporters that localize at the apical membrane surface of renal proximal tubules. SLC22A18 is expressed at high levels in the kidney, liver, colon and in fetal renal proximal tubules and present at lower levels in heart, brain and lung. Defects in SLC22A18 are associated with breast and lung cancer and are the cause of rhabdomyosarcoma type 1, a malignant tumor derived from striated muscle. More recently, SLC22A18 has been shown to functions as a tumor suppressor in glioma and represents a candidate biomarker for long-term survival in this disease.

Protocols

Product Specific Protocols
WB protocol for SLC22A18 antibody 11646-2-APDownload protocol
IP protocol for SLC22A18 antibody 11646-2-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Int J Biol Macromol

microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18.

Authors - Bicheng Zhang
  • KD Validated

Hum Mol Genet

Parent-of-origin tumorigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumor modifiers.

Authors - Attje S Hoekstra
humanIHC

Cancer Epidemiol

Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery.

Authors - He Hongyu H